May 29, 2014 06:30 ET
WINNIPEG, MANITOBA--(Marketwired - May 29, 2014) - Miraculins Inc. (TSX VENTURE:MOM) (the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces that at today's annual and special meeting of shareholders (the "Meeting"), Harry Bloomfield QC, Christopher Moreau, William Roberts and Michael Stasiuk were reelected as directors of the Company to hold office until the next annual meeting of shareholders, or until their successors are duly elected or appointed. James Mellon had advised the Company prior to the Meeting that he would not be standing for reelection.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Miraculins Inc.Christopher J. MoreauPresident & CEO204-477-7599204-453-1546 (FAX)email@example.com
See all RSS Newsfeeds